Adrenal insufficiency and adrenal replacement therapy. Current status in Spain;Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España

Endocrinologia y Nutricion

Volumn 60, Issue 3, 2013, Pages 136-143

  Aulinas, Anna ^a   Casanueva, Felipe ^b   Goñi, Fernando ^c   Monereo, Susana ^d   Moreno, Basilio ^e   Picó, Antonio ^f   Puig Domingo, Manel ^g   Salvador, Javier ^h   Tinahones, Francisco J ⁱ   Webb, Susan M ^a,j  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^j UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Addison's disease; Adrenal insufficiency; Corticotropin deficiency; Hydrocortisone; Morbidity; Mortality

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE;

ADRENAL GLAND; ADRENAL INSUFFICIENCY; DRUG BIOAVAILABILITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; SHORT SURVEY; SPAIN; SUBSTITUTION THERAPY;

ADRENAL CORTEX HORMONES; ADRENAL INSUFFICIENCY; HORMONE REPLACEMENT THERAPY; HUMANS; PRACTICE GUIDELINES AS TOPIC; SPAIN;

EID: 84875098730     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.12.002     Document Type: Short Survey

References (41)

1. Smans L.C., Zelissen P.M. Does recovery of adrenal function occur in patients with autoimmune Addison's disease?. Clin Endocrinol (Oxf) 2011, 74:434-437.
2. Laureti S., Vecchi L., Santeusanio F., Falorni A. Is the prevalence of Addison's disease underestimated?. J Clin Endocrinol Metab 1999, 84:1762.
3. Arlt W., Allolio B. Adrenal insufficiency. Lancet 2003, 361:1881-1893.
4. Regal M., Páramo C., Sierra J.M., García-Mayor R.V. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001, 55:735-740.
5. Simon N., Castinetti F., Ouliac F., Lesavre N., Brue T., Oliver C. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets. Clin Pharmacokinet 2010, 49:456-463.
6. Debono M., Price J.N., Ross R.J. Novel strategies for hydrocortisone replacement. Best Pract Res Clin Endocrinol Metab 2009, 23:221-232.
7. Esteban N.V., Loughlin T., Yergey A.L., Zawadzki J.K., Booth J.D., Winterer J.C., et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endoc Metab 1991, 72:39-45.
8. Crown A., Lightman S. Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf) 2005, 63:483-492.
9. Bergthorsdottir R., Leonsson-Zachrisson M., Odén A., Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006, 91:4849-4853.
10. Bensing S., Brandt L., Tabaroj F., Sjöberg O., Nilsson B., Ekbom A., et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008, 69:697-704.
11. Erichsen M.M., Løvås K., Fougner K.J., Svartberg J., Hauge E.R., Bollerslev J., et al. Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol 2009, 160:233-237.
12. Rosén T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
13. Bates A.S., Van't Hoff W., Jones P.F., Clayton R.N. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996, 81:1169-1172.
14. Bülow B., Hagmar L., Mikoczy Z., Nordström C.H., Erfurth E.M. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997, 46:75-81.
15. Tomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001, 357:425-431. West Midlands Prospective Hypopituitary Study Group.
16. Mills J.L., Schonberger L.B., Wysowski D.K., Brown P., Durako S.J., Cox C., et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004, 144:430-436.
17. Bleicken B., Hahner S., Loeffler M., Ventz M., Allolio B., Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008, 159:811-817.
18. Hahner S., Loeffler M., Fassnacht M., Weismann D., Koschker A.C., Quinkler M., et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007, 92:3912-3922.
19. Forss M., Batcheller G., Skrtic S., Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocr Disord 2012, 12:8. 10 1186/1472-6823-12-8.
20. Filipsson H., Monson J.P., Koltowska-Häggström M., Mattsson A., Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006, 91:3954-3961.
21. Dallman M.F., Akana S.F., Bhatnagar S., Bell M.E., Strack A.M. Bottomed out: metabolic significance of the circadian trough in glucocorticoid concentrations. Int J Obes Relat Metab Disord 2000, 24:S40-S46.
22. Løvås K., Gjesdal C.G., Christensen M., Wolff A.B., Almås B., Svartberg J., et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009, 160:993-1002.
23. Hereux F., Maiter D., Boutsen Y., Devogelaer J.P., Jamart J., Donckier J. Evaluation of corticosteroid replacement therapy and its effect on bones in Addison's disease. Ann Endocrinol (Paris) 2000, 61:179-183.
24. Zelissen P.M., Croughs R.J., van Rijk P.P., Raymakers J.A. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison's disease. Ann Intern Med 1994, 120:207-210.
25. Koetz K.R., Ventz M., Diederich S., Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012, 97:85-92.
26. Jódar E., Valdepeñas M.P., Martínez G., Jara A., Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf) 2003, 58:617-620.
27. Björnsdottir S., Sääf M., Bensing S., Kämpe O., Michaëlsson K., Ludvigsson J.F. Risk of hip fracture in Addison's disease: a population-based cohort study. J Intern Med 2011, 270:187-195.
28. Alonso N., Granada M.L., Lucas A., Salinas I., Reverter J., Oriol A., et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients. Effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest 2004, 27:449-454.
29. Groves R.W., Toms G.C., Houghton B.J., Monson J.P. Corticosteroid replacement therapy: twice or thrice daily?. J R Soc Med 1988, 81:514-516.
30. Plat L., Leproult R., L'Hermite-Baleriaux M., Fery F., Mockel J., Polonsky K.S., et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999, 84:3082-3092.
31. Matthews K., Schwartz J., Cohen S., Seeman T. Diurnal cortisol decline is related to coronary calcification: CARDIA study. Psychosom Med 2006, 68:657-661.
32. Vgontzas A.N., Bixler E.O., Lin H.M., Prolo P., Mastorakos G., Vela-Bueno A., et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001, 86:3787-3794.
33. Gangwisch J.E. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. Obes Rev 2009, 10:37-45.
34. Buckley T.M., Schatzberg A.F. On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J Clin Endocrinol Metab 2005, 90:3106-3114.
35. García-Borreguero D., Wehr T.A., Larrosa O., Granizo J.J., Hardwick D., Chrousos G.P., et al. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency. J Clin Endocrinol Metab 2000, 85:4201-4206.
36. Løvås K., Husebye E.S. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007, 157:109-112.
37. Johannsson G., Nilsson A.G., Bergthorsdottir R., Burman P., Dahlqvist P., Ekman B., et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012, 97:473-481.
38. Johannsson G., Filipsson H., Bergthorsdottir R., Lennernäs H., Skrtic S. Long-acting hydrocortisone for glucocorticoid replacement therapy. Horm Res 2007, 68:182-188.
39. Johannsson G., Bergthorsdottir R., Nilsson A.G., Lennernäs H., Hedner T., Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009, 161:119-130.
40. Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, et al. An open, multi-centre, phase IIIB, long-term follow-up study to assess the safety, tolerability and efficacy of once-daily oral dual-release hydrocortisone in patients with adrenal insufficiency. P78 presented at ICE-ECE 2012; Florence.
41. Simonsson US, Skrtic S, Lennernäs H, Johannsson G. Intercurrent illness dose regimen in adrenal insufficiency with a dual-release hydrocortisone formulation derived from population pharmacokinetic modelling. P50 presented at ICE-ECE 2012; Florence.